Whole Genome Amplification Market Snapshot
As demand of whole genome amplification (WGA) in forensics and in the study of genetic disorders is on the rise, whole genome amplification market valuation is expected surpass US$ 5087.40 Mn by the end of 2031, reports Future Market Insights (FMI) in its market analysis.
As per the analysis, Europe will provide lucrative growth opportunities for whole genome amplification market owing to rising prevalence of cancer and establishment of advance healthcare system in the regions like Germany and U.K. Spurred by this, the Europe WGA market is projected to grow at about 8.5% CAGR during the forecast period.
Key Points Covered in Whole genome amplification Market Study
- Market estimates and forecast 2021 – 2031
- Key drivers and restrains impacting market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competitive Mapping and Benchmarking
- Brand share and Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact On Whole Genome Amplification Market and How to Navigate
- Recommendation on Key Winning Strategies
2016 – 2020 Whole genome amplification Market Outlook In Comparison to 2021 – 2031 Forecasts
Rising incidence of cancer, cardiovascular ailments and heart diseases has driven the whole genome amplification market in past few years. As per the FMI, whole genome amplification sales rose at 5.7% CAGR between 2016 and 2020.
Increasing awareness and rise in initiatives to spread information about the method of whole genome amplification will create lucrative market growth opportunities during the forecast period.
10x Genomics released a novel single cell whole genome amplification kit for low throughput analysis of single-cell gene expression in April 2021. The kit lowers the experiment cost and assists in optimization of experimental condition as it profiles expression for 100 to 1,000 single cells.
In October 2020, BioSkryb launched its new ResolveDNATM kits incorporated with primary template-directed amplification (PTA) technology, to accurately and uniformly amplify the genomes of single cells.
The company announced its first set of data in December 2020, suggesting that the new PTA technology enhances accuracy in single cell WGA analysis. The novel technology captures around 95% of single cell’s genome to give accurate and consistent data.
Increasing innovation to increase the reliability of the wide range of whole genome amplification kits and heavy investment from market players for new product development will boost the global whole genome amplification market sales in the near future.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Preference for single-cell whole genome amplification to prevail
Single-cell whole genome amplification is the highly preferred product type in the global market. Advances in primer technologies and lysing techniques have led to more reliable and accurate whole cell genome amplification. Single cell WGA is used to examine the sequence information with the optimized next generation technologies, only from a single cell.
This method is considered to be a powerful tool that helps to understand the ins and outs of genetics by bringing the entire genome structure to a cellular level. Since this method offers a high-resolution view of the genomic sample, its adoption will continue to be on the rise in diverse biological fields such as microbiology, immunology, neurobiology, cancer research, and tissue mosaicism.
Single cell WGA plays a crucial role in conveying new applications to the market. Moreover, screening for a variety of developmental and neurological genetic disorders is heavily dependent on single-cell WGA. These experiments are conducted with an RT-PCR utilizing specific WGA PCR kits.
GenomePlex WGA4 kits from Sigma-Aldrich are among a few kits on the market specifically designed for single-cell WGA. Most other kits can be used for either single cells or, more commonly, pool of cells. Leading companies that are dealing in single-cell kits are Sigma-Aldrich (in association with Rubicon Genomics), QIAGEN NV, and GE Healthcare.
According to the market forecast recently provided by Future Market Insights, single-cell WGA Kits are projected to reach a market value of over US$ 2,000 Mn by the end of 2031.
Device & kits manufacturers to abide by FDA’s safety legislations to improve accuracy and efficiency
There is an increase in the safety rules and legislations which is expected to improve accuracy and efficiency significantly. It is also intended to avoid false positivity of whole genome amplification and boost the quality of diagnostic services. To focus more on safety, the U.S. FDA has provided a guideline such as 510-K.
This section of Food Drug and Cosmetic Act, also known as Pre-market Approval, recommends device and kits manufacturers to mandatorily register and notify FDA of their intent to promote their product at least 90 days in advance. These improvements are projected to bolster the growth of the global whole genome amplification market.
Introduction of custom product offerings to hit market, as a new strategic move
The research community has to cater to evolving needs, which in turn requires manufacturing of special custom products. The demand for specialized tools and reagents has grown to the point where most vendors currently offering these products cannot depend solely on the sale of the catalog products.
The custom requirements demand special time management which depends on the vendor choices. Research users tend to prefer tried-and-tested solutions for their custom reagent needs to avoid the time and effort to validate custom products prior to use in critical experiments.
Product recalls and safety concerns may deter market growth
The process of WGA involves extraction, amplification and sequencing. The PCR-based WGA and REPLI-g technology has different results. Single base-pair mutations, STR contractions, and expansions, and also biased and underrepresented loci are involved in PCR WGA.
Whereas, REPLI-g technology, which uses MDA technology and Phi 29 polymerase, delivers highly uniform amplification across the entire genome with minimal locus bias during amplification. This leads to a lack of trust on the process, which declines the revenue of whole genome amplification market.
Whole genome amplification Market – Report Scope
2021 – 2031
Historical Data Available for
2018 – 2028
US$ Mn for Value & Units for Volume
Key Regions Covered
North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East and Africa
Key Countries Covered
U.S., Canada, Brazil, Mexico, Argentina, Rest of Latin America, EU-5, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Denmark, Finland, Iceland, Norway, Sweden), Rest of Western Europe, Poland, Russia, Rest of Eastern Europe, China, India, Japan, GCC Countries, South Africa, Israel, Turkey, Iran, Rest of Middle East & Africa, Australia, New Zealand, South Korea, the Philippines, Malaysia, and Thailand
Key Segments Covered
Product type, Application Type, Distribution channel, and Region
Key Companies Profiled
Market Overview, Market Background, Market Forecast, Segmental Analysis, Regional Profiling and Competition Analysis
Customization & Pricing
Available upon Request
Key Questions Answered in the Report
How much is the whole genome amplification market worth?
The market valuation of whole genome amplification experienced a year-o-year growth of 8% from 2020 to 2021. The whole genome amplification market is worth around US$ 2378.3Mn in 2021
At what rate did the whole genome amplification market expand in the last five years?
Between 2016 and 2020, the whole genome amplification sales surged at a 5.7% CAGR. The market’s valuation stood at US$ 2202.3Mn in 2020.
What will be the demand outlook/ sales forecast of whole genome amplification market?
Increasing advancement in the field of DNA sequencing and genome amplification, the sales of whole genome amplification kit will increase by 2.13 times, reaching a market valuation of US$ 5087.4 Mn by the end of 2031.
Which countries are key producers of whole genome amplification?
U.S., U.K., and Germany are the leading manufacturers for whole genome amplification kits owing to increasing government and private funding for healthcare development and presence of leading market players in the country.
What is the North America whole genome amplification market outlook?
Demand registered in North America will continue rising, backed increasing sales in the U.S. and Canada, the North America market will account for 38% of global demand of whole genome amplification kits.
Which are the key exporters of whole genome amplification?
GE Healthcare, Merck KGaA, and Thermo Fisher Scientific Inc., and Active Motif are the key exporters operating in the whole genome amplification market.
What is the cumulative share of top ten companies in whole genome amplification market?
Top players account for 70% of the whole genome amplification market. They are responsible for 7 out of 10 sales of WGA kits across the world.
At what percentage whole genome amplification is going to register growth in Europe?
Whole genome amplification sales will increase at 8.5% CAGR in Europe, backed by rising demand in the U.K., Germany, and other countries.
Which are the top five countries driving whole genome amplification market demand?
Leading countries driving demand in the whole genome amplification market are the U.S., U.K., Germany, Japan, and China.
What is the key market statistics in Japan and China for whole genome amplification market?
Japan and China held 9.7% and 4.6% share respectively in the overall whole genome amplification market in 2021.
Key Segments Covered in Whole genome amplification Market Study
By Product Type
- Single Cell WGA Kit
- Complete WGA Kit
- WGA Re-Amplification Kit
- WGA & Chip DNA Kit
- Drug Discovery & Development
- Disease Diagnosis
- Agriculture & Veterinary
By End User
- Pharma & Biotech Companies
- Hospitals & Clinics
- Contract Research
- Research & Academic Institutes
- North America
- Latin America
- Western Europe
- Eastern Europe
- Middle East & Africa (MEA)